CN1158254C - 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸 - Google Patents

作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸 Download PDF

Info

Publication number
CN1158254C
CN1158254C CNB971979227A CN97197922A CN1158254C CN 1158254 C CN1158254 C CN 1158254C CN B971979227 A CNB971979227 A CN B971979227A CN 97197922 A CN97197922 A CN 97197922A CN 1158254 C CN1158254 C CN 1158254C
Authority
CN
China
Prior art keywords
methyl
alkylsulfonyl
hydroxyl
propionic acid
acid amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971979227A
Other languages
English (en)
Chinese (zh)
Other versions
CN1230177A (zh
Inventor
Ma
M·A·瓦比霍斯基
D·E·哈朋尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of CN1230177A publication Critical patent/CN1230177A/zh
Application granted granted Critical
Publication of CN1158254C publication Critical patent/CN1158254C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB971979227A 1996-09-27 1997-09-19 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸 Expired - Fee Related CN1158254C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
US60/026,848 1996-09-27

Publications (2)

Publication Number Publication Date
CN1230177A CN1230177A (zh) 1999-09-29
CN1158254C true CN1158254C (zh) 2004-07-21

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971979227A Expired - Fee Related CN1158254C (zh) 1996-09-27 1997-09-19 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸

Country Status (21)

Country Link
US (2) US6235928B1 (https=)
EP (1) EP0929519B1 (https=)
JP (1) JP2001516338A (https=)
KR (1) KR20000048639A (https=)
CN (1) CN1158254C (https=)
AT (1) ATE289590T1 (https=)
AU (1) AU726799B2 (https=)
BR (1) BR9712134A (https=)
CA (1) CA2266368A1 (https=)
CZ (1) CZ92399A3 (https=)
DE (1) DE69732571T2 (https=)
EA (1) EA001460B1 (https=)
ES (1) ES2236829T3 (https=)
HU (1) HUP0000145A3 (https=)
ID (1) ID21897A (https=)
IL (1) IL128900A0 (https=)
NO (1) NO312893B1 (https=)
NZ (1) NZ334729A (https=)
PL (1) PL332509A1 (https=)
UA (1) UA48262C2 (https=)
WO (1) WO1998013340A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
DE69729007T2 (de) * 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
WO1998013340A1 (en) * 1996-09-27 1998-04-02 Pharmacia & Upjohn Company β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
EP0960096B1 (en) 1997-01-22 2005-04-06 Aventis Pharmaceuticals Inc. Substituted beta-thiocarboxylic acids
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6380258B2 (en) * 1997-03-04 2002-04-30 G. D. Searle, L.L.C. Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
IL135586A0 (en) * 1997-11-21 2001-05-20 Upjohn Co α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
EP1357109B1 (en) 1998-06-18 2008-07-23 F. Hoffmann-La Roche Ag Process for aryl alkyl sulfide
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2632030A1 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2081905B1 (en) * 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
CA2664310A1 (en) * 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
JP5492092B2 (ja) * 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2326629B1 (en) * 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
WO2010036630A2 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
JP2013505295A (ja) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5525629A (en) * 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
JP4358908B2 (ja) * 1996-01-02 2009-11-04 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換（アリール、ヘテロアリール、アリールメチル又はヘテロアリールメチル）ヒドロキサム酸化合物
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
WO1998013340A1 (en) 1996-09-27 1998-04-02 Pharmacia & Upjohn Company β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Also Published As

Publication number Publication date
DE69732571D1 (de) 2005-03-31
AU4645997A (en) 1998-04-17
NO991494D0 (no) 1999-03-26
NZ334729A (en) 2001-01-26
US5847153A (en) 1998-12-08
EA199900332A1 (ru) 1999-12-29
NO991494L (no) 1999-05-26
ATE289590T1 (de) 2005-03-15
ES2236829T3 (es) 2005-07-16
DE69732571T2 (de) 2006-01-12
HUP0000145A3 (en) 2001-12-28
EP0929519A1 (en) 1999-07-21
ID21897A (id) 1999-08-05
CZ92399A3 (cs) 1999-07-14
HUP0000145A2 (en) 2000-07-28
BR9712134A (pt) 1999-08-31
AU726799B2 (en) 2000-11-23
EP0929519B1 (en) 2005-02-23
US6235928B1 (en) 2001-05-22
PL332509A1 (en) 1999-09-13
NO312893B1 (no) 2002-07-15
EA001460B1 (ru) 2001-04-23
WO1998013340A1 (en) 1998-04-02
IL128900A0 (en) 2000-01-31
CN1230177A (zh) 1999-09-29
HK1022468A1 (en) 2000-08-11
CA2266368A1 (en) 1998-04-02
JP2001516338A (ja) 2001-09-25
KR20000048639A (ko) 2000-07-25
UA48262C2 (uk) 2002-08-15

Similar Documents

Publication Publication Date Title
CN1158254C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸
CN1168709C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸的α-羟基、-氨基和卤代衍生物
CN1188407C (zh) 具有法尼基转移酶抑制活性的咪唑衍生物及其制备方法
CN1207289C (zh) 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
CN1273444C (zh) 二肽腈
CN1213025C (zh) 硫代酰胺衍生物
CN1098838C (zh) 被取代的N－(吲哚－2－羰基)－β－丙氨酰胺与作为抗糖尿病药的衍生物
CN1245394C (zh) 作为葡糖激酶激活剂的取代的苯乙酰胺及其用途
CN1075062C (zh) 乙酸衍生物
CN1016778B (zh) 螺-取代的戊二酸单酰胺
CN1276785A (zh) N－烷酰基苯丙氨酸衍生物
CN1374082A (zh) 糖原磺酸化酶抑制剂的用途
CN1040986A (zh) 环烷基取代的戊二酰胺衍生物的制备
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN1134153A (zh) 基质金属蛋白酶抑制剂
CN1390196A (zh) 具有药理活性的新的二羧酸衍生物
CN1228772A (zh) 杂环金属蛋白酶抑制剂
CN1291184A (zh) 环烯衍生物、其制造方法和用途
CN101031555A (zh) 具有vap－1抑制活性的噻唑衍生物
CN1068815A (zh) 用做抗炎及抗变性剂的新的取代氮杂环丁酮
CN1906164A (zh) 组织蛋白酶半胱氨酸蛋白酶抑制剂
HK1042691A1 (zh) 磺酰胺异羟肟酸脂
CN1107857A (zh) 环状氨基酸衍生物
CN1284942A (zh) 基质金属蛋白酶抑制剂
CN1067072C (zh) 三环化合物、它们的制备及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1022468

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee